Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Remepy","sponsor":"NFX","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Remepy Launches with $15 Million in Funding to Bring First Hybrid Drug to Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Remepy

    Menu

    Remepy

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Remepy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Remepy Launches with $15 Million in Funding to Bring First Hybrid Drug to Market

              Details:

              Remepy is pioneering Hybrid Drugs, traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments targeting neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: NFX

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Financing May 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY